Related Experiment Videos
Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits
Insights
LDL apheresis with the Liposorber system removes LDL cholesterol in patients unresponsive to other treatments. This therapy significantly improves endothelial function and reduces cardiac events, offering hope for cardiovascular health.
Area of Science:
- Cardiovascular Medicine
- Biomedical Engineering
- Nephrology
Background:
- LDL apheresis using the Liposorber system targets hypercholesterolemia unresponsive to diet and medication.
- The system utilizes dextran sulfate immobilized on cellulose beads as a pseudoreceptor for LDL removal.
Discussion:
- Liposorber treatment demonstrates significant clinical benefits, including improved endothelial cell function in coronary and brachial arteries.
- A notable finding is a 70% reduction in cardiac events compared to drug therapy alone.
Key Insights:
- Selective LDL removal via apheresis offers a potent therapeutic strategy for severe hypercholesterolemia.
- The system's efficacy extends beyond familial hypercholesterolemia, with potential applications in arteriosclerosis obliterans and focal glomerular sclerosis.
Outlook:
- Further research into Liposorber's impact on vascular and renal conditions is warranted.
- Exploring the long-term benefits and broader applications of LDL apheresis in managing complex cardiovascular and renal diseases is crucial.
Abstract:
LDL apheresis using the Liposorber system is indicated for use to remove selectively LDL from the plasma of hypercholesterolemic patients for whom diet and maximum cholesterol-lowering drug therapy have been ineffective or not tolerated. The dextran sulfate immobilized to porous cellulose beads is contained in the adsorption column as the adsorbent. The dextran sulfate has a structure similar to that of the LDL receptor and seems to act as a type of pseudoreceptor for LDL. There have been reported a number of clinical benefits using the Liposorber system for drug refractory hypercholesterolemic patients. Among them, the improvement of endothelial cell function of coronary and brachial arteries by a single treatment is the focus of the world's attention. Moreover, it is also noteworthy that LDL apheresis reduced the incidence of the cardiac events by 70% compared to drug therapy alone. In addition to the clinical benefits of the Liposorber system on familial hypercholesterolemia (FH), the preliminary data suggest that LDL apheresis may improve arteriosclerosis obliterans (ASO) of the lower extremities and focal glomerular sclerosis (FGS).